Drug Trial Radar · NCT07077434
A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Jan 19, 2027
Study completion Jan 19, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
BMS-986504Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of BMS-986504Time frame: Up to approximately Day 64
- Time to Reach Maximum Plasma Concentration (Tmax) of BMS-986504Time frame: Up to approximately Day 64
- Area Under Curve (AUC) of BMS-986504Time frame: Up to approximately Day 64
- Mean Elimination Half-life (T-HALF) of BMS-986504Time frame: Up to approximately Day 64
- Apparent Total Body Clearance (CLT/F) of BMS-986504Time frame: Up to approximately Day 64
- Apparent Volume of Distribution During the Terminal Phase (Vz/F) of BMS-986504Time frame: Up to approximately Day 64
Locations
12 sites in 2 countries. Site status is shown where the registry gives one.
Beijing Cancer hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Kanagawa cancer center
Yokohama, Kanagawa, Japan · Recruiting
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan · Recruiting
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan · Recruiting
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.